What is the significance of Tom Graney's appointment as CFO?

Tom Graney's appointment as CFO signifies a strategic leadership change in Vertex Pharmaceuticals' financial operations. His experience from companies like Ironwood Pharmaceuticals and Johnson & Johnson is expected to bring valuable financial expertise and strategic direction to the company as it pursues its growth objectives.

What is Ian Smith's new role?

Ian Smith, the former CFO, is transitioning to the role of Executive Vice President and Chief Operating Officer. This indicates a reshuffling of executive responsibilities, potentially to better align with the company's operational and strategic needs.

What are the key components of Tom Graney's compensation package?

Mr. Graney's compensation includes an annual base salary of $550,000, a one-time sign-on cash bonus of $150,000, and a restricted stock unit grant valued at $1,500,000, which will vest over time. He will also participate in the company's annual cash bonus and equity programs.

What are the change of control provisions for Tom Graney?

The change of control agreement provides Mr. Graney with specific benefits if his employment is terminated without cause or if he resigns for good reason within a defined period (90 days before to 12 months after) a change of control event. These benefits include salary and target bonus continuation, a pro-rated performance bonus, and accelerated vesting of equity awards.

VRTX 8-K: Leadership Changes

Summary

Vertex Pharmaceuticals Inc. (VRTX) announced a significant leadership change in its finance department via an 8-K filing on September 6, 2017. Tom Graney has been appointed as the new Senior Vice President and Chief Financial Officer (CFO), effective September 13, 2017. This transition sees the current CFO, Ian Smith, stepping into the role of Executive Vice President and Chief Operating Officer, indicating a strategic realignment of key executive responsibilities within the company. Mr. Graney brings a wealth of experience from his previous roles at Ironwood Pharmaceuticals and Johnson & Johnson, including extensive financial leadership and strategic planning expertise, which will be crucial as Vertex continues its growth and development initiatives. The appointment of Mr. Graney is accompanied by a comprehensive compensation package, including a base salary of $550,000, a sign-on bonus of $150,000, and a substantial restricted stock unit grant valued at $1,500,000. Additionally, the filing details severance provisions under both his employment agreement and a change of control agreement, offering financial security in specific termination scenarios. Investors should note these executive changes and their associated financial arrangements as they reflect on the company's ongoing operational strategy and executive team stability.

Key Highlights

1Vertex Pharmaceuticals appointed Tom Graney as Senior Vice President, Chief Financial Officer, effective September 13, 2017.
2Current CFO, Ian Smith, will transition to Executive Vice President and Chief Operating Officer.
3Tom Graney has extensive financial leadership experience, most recently as CFO of Ironwood Pharmaceuticals and prior roles at Johnson & Johnson.
4Mr. Graney's compensation includes a base salary of $550,000, a $150,000 sign-on bonus, and a $1,500,000 restricted stock unit grant.
5The company entered into an employment agreement and a change of control agreement with Mr. Graney.
6Severance provisions are outlined for termination without cause or for good reason, with enhanced benefits in the event of a change of control.
7Mr. Graney also serves on the board of directors of AC Immune SA.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Sep 6, 2017)

Summary

Key Highlights

Frequently Asked Questions